stockrow
Saturday 7 November 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
- EPS
- +24.3%
- Free cash flow
- +33.7%
Quarter to June 2026, against a year earlier
11.34
0.54
+5.00%
Follow CGEM
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.23 | 10.01 | 10.01 | 10.15 | |
Current Ratio |
8.42 | 10.28 | 10.25 | 10.45 | |
Net Debt/EBITDA |
5.85 | 6.56 | 6.85 | 5.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.93 | 0.75 | 0.73 | |
Capex/Depreciation |
0.00 | 0.00 | (0.14) | (0.48) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.62) | (0.76) | (0.65) | (0.62) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.62) | (0.76) | (0.65) | (0.62) | |
Cash per Share |
5.44 | 5.82 | 6.40 | 5.63 | |
Shareholders Equity per Share |
5.23 | 6.06 | 6.92 | 7.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.23 | 6.06 | 6.92 | 7.64 | |
Free Cash Flow |
(38.22) | (46.04) | (38.12) | (36.91) | |
Working Capital |
301.35 | 326.25 | 349.02 | 309.48 | |
Capital Expenditures |
— | — | (0.01) | (0.04) | |
Net Current Asset Value |
299.94 | 324.60 | 347.11 | 309.48 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.09 | 2.96 | 1.26 | 1.92 | |
Average Assets |
442.06 | 491.33 | 535.10 | 568.69 | |
Average Common Equity |
406.95 | 459.01 | 499.53 | 539.62 |
Columns are period end dates · fundamentals updated 25 Oct 2026